as 12-18-2024 9:48am EST
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
Founded: | 2012 | Country: | United States |
Employees: | N/A | City: | N/A |
Market Cap: | 65.5M | IPO Year: | 2021 |
Target Price: | $8.00 | AVG Volume (30 days): | 31.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.39 | EPS Growth: | N/A |
52 Week Low/High: | $0.77 - $2.66 | Next Earning Date: | 09-05-2024 |
Revenue: | $24,116,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 63.90% |
CNTB Breaking Stock News: Dive into CNTB Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago
Simply Wall St.
4 months ago
GlobeNewswire
6 months ago
GlobeNewswire
6 months ago
MT Newswires
6 months ago
The information presented on this page, "CNTB Connect Biopharma Holdings Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.